Identification of the ß-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells

Oncotarget

Volumn 6, Issue 36, 2015, Pages 38999-39017

  Lin, Yi Te ^a   Chao, Chuck C K ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Apoptosis; Hepatocellular carcinoma; Prothymosin; Sorafenib; catenin

Indexed keywords

BETA CATENIN; CASPASE 3; CASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTHYMOSIN ALPHA; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CTNNB1 PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN PRECURSOR; THYMOSIN;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER RESISTANCE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PTMA GENE; RNA DEGRADATION; TRANSCRIPTION REGULATION; UPREGULATION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HUMAN; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN PRECURSORS; THYMOSIN; TRANSFECTION;

EID: 84948754425     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5738     Document Type: Article

References (63)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005; 55:74-108.
2. Jiang X, Kim H-E, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng S-c, Rosenberg S, Wang X. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 2003; 299:223-226.
3. Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochemical pharmacology. 2011; 82:184-194.
4. Tsou AP, Yang CW, Huang CY, Yu RC, Lee YC, Changx CW, Chen BR, Chung YF, Fann MJ, Chi CW, Chiu JH, Chou CK. Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma. Oncogene. 2003; 22:298-307.
5. Wu CG, Habib NA, Mitry RR, Reitsma PH, van Deventer SJ, Chamuleau RA. Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. British journal of cancer. 1997; 76:1199-1204.
6. Lin YT, Lu HP, Chao CC. Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. Biochemical pharmacology. 2015; 93:110-124.
7. Polakis P. The oncogenic activation of beta-catenin. Current opinion in genetics&development. 1999; 9:15-21.
8. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6:674-687.
9. Shibata T, Aburatani H. Exploration of liver cancer genomes. Nature reviews Gastroenterology&hepatology. 2014; 11:340-349.
10. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95:8847-8851.
11. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer research. 1998; 58:2524-2527.
12. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009; 49:821-831.
13. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, Hauptschein R, Rejto PA, Fernandez J, Wang G, Zhang Q, Wang B, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome research. 2013; 23:1422-1433.
14. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature medicine. 2012; 18:1359-1368.
15. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. Journal of hepatology. 2013; 59:1107-1117.
16. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Current pharmaceutical design. 2002; 8:2255-2257.
17. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research. 2004; 64:7099-7109.
18. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M. BAY 43-9006 inhibition of oncogenic RET mutants. Journal of the National Cancer Institute. 2006; 98:326-334.
19. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer cell. 2011; 19:86-100.
20. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways. Anticancer research. 2014; 34:1709-1713.
21. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:4997-5007.
22. Muche S, Kirschnick M, Schwarz M, Braeuning A. Synergistic effects of beta-catenin inhibitors and sorafenib in hepatoma cells. Anticancer research. 2014; 34:4677-4683.
23. Barbini L, Gonzalez R, Dominguez F, Vega F. Apoptotic and proliferating hepatocytes differ in prothymosin alpha expression and cell localization. Molecular and cellular biochemistry. 2006; 291:83-91.
24. Mori M, Barnard GF, Staniunas RJ, Jessup JM, Steele GD Jr, Chen LB. Prothymosin-alpha mRNA expression correlates with that of c-myc in human colon cancer. Oncogene. 1993; 8:2821-2826.
25. Shibuta K, Mori M, Mimori K, Inoue H, Nakashima H, Baba K, Haraguchi M, Karimine N, Ueo H, Akiyoshi T. Expression of prothymosin-alpha and c-myc mRNA in human gastric cancer. International journal of oncology. 1996; 9:247-251.
26. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Expression of the prothymosin a mRNA correlated with that of N-myc in neuroblastoma. Cancer letters. 2001; 168:191-195.
27. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the alpha-prothymosin gene. The EMBO journal. 1991; 10:133-141.
28. Gaubatz S, Meichle A, Eilers M. An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc. Molecular and cellular biology. 1994; 14:3853-3862.
29. Mol PC, Wang R-H, Batey DW, Lee LA, Dang CV, Berger SL. Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene? Molecular and cellular biology. 1995; 15:6999-7009.
30. Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettnerl R, Eilers M. Transcriptional activation by Myc is under negative control by the transcription factor AP-2. The EMBO journal. 1995; 14:1508-1519.
31. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E, Galindo M, Antonelli M, Marcelain K, Armisen R, Tapia JC. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Molecular and cellular biochemistry. 2011; 356:127-132.
32. Iqbal S, Zhang S, Driss A, Liu ZR, Kim HR, Wang Y, Ritenour C, Zhau HE, Kucuk O, Chung LW, Wu D. PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. PloS one. 2012; 7:e30764.
33. Shen L, Zhang X, Hu D, Feng T, Li H, Lu Y, Huang J. Hepatitis B virus X (HBx) play an anti-apoptosis role in hepatic progenitor cells by activating Wnt/beta-catenin pathway. Molecular and cellular biochemistry. 2013; 383:213-222.
34. Augustin I, Goidts V, Bongers A, Kerr G, Vollert G, Radlwimmer B, Hartmann C, Herold-Mende C, Reifenberger G, von Deimling A, Boutros M. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO molecular medicine. 2012; 4:38-51.
35. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. The EMBO journal. 1989; 8:1711-1717.
36. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature. 2005; 437:281-285.
37. Toualbi K, Guller MC, Mauriz JL, Labalette C, Buendia MA, Mauviel A, Bernuau D. Physical and functional cooperation between AP-1 and beta-catenin for the regulation of TCF-dependent genes. Oncogene. 2007; 26:3492-3502.
38. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012; 18:4997-5007.
39. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001; 92:136-145.
40. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, Ohgaki H. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. The American journal of pathology. 1999; 155:1795-1801.
41. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001; 120:1763-1773.
42. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature genetics. 2012; 44:694-698.
43. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY, Park CK. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver international: official journal of the International Association for the Study of the Liver. 2005; 25:70-76.
44. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002; 21:4863-4871.
45. Amaddeo G, Guichard C, Imbeaud S, Zucman-Rossi J. Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncoimmunology. 2012; 1:1612-1613.
46. Suzuki T, Yano H, Nakashima Y, Nakashima O, Kojiro M. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. Journal of gastroenterology and hepatology. 2002; 17:994-1000.
47. Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB, Slagle BL, Wands JR. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology. 2009; 49:1935-1943.
48. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000; 21:485-495.
49. Sun NK, Huang SL, Chang TC, Chao CC. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3beta-dependent protein degradation. Journal of cellular biochemistry. 2013; 114:1819-1831.
50. Wang Q, Lu TL, Adams E, Lin JL, Lin JJ. Intercalated disc protein, mXinalpha, suppresses p120-catenin-induced branching phenotype via its interactions with p120-catenin and cortactin. Archives of biochemistry and biophysics. 2013; 535:91-100.
51. Risse G, Jooss K, Neuberg M, Bruller HJ, Muller R. Asymmetrical recognition of the palindromic AP1 binding site (TRE) by Fos protein complexes. The EMBO journal. 1989; 8:3825-3832.
52. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97:4262-4266.
53. Tinti C, Yang C, Seo H, Conti B, Kim C, Joh TH, Kim KS. Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription. The Journal of biological chemistry. 1997; 272:19158-19164.
54. Sambrook J, Russell D.W. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory (3rd ed)2001;.
55. Sun CL, Chao CC. Cross-resistance to death ligand-induced apoptosis in cisplatin-selected HeLa cells associated with overexpression of DDB2 and subsequent induction of cFLIP. Molecular pharmacology. 2005; 67:1307-1314.
56. Wu ZZ, Lu HP, Chao CC. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochemical pharmacology. 2010; 80:262-276.
57. Kamarajan P, Sun NK, Sun CL, Chao CC. Apaf-1 overexpression partially overcomes apoptotic resistance in a cisplatin-selected HeLa cell line. FEBS letters. 2001; 505:206-212.
58. Chao CC, Huang SL, Huang HM, Lin-Chao S. Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified, DNA. Molecular and cellular biology. 1991; 11:2075-2080.
59. Tsai SY, Sun NK, Lu HP, Cheng ML, Chao CC. Involvement of reactive oxygen species in multidrug resistance of a vincristine-selected lymphoblastoma. Cancer science. 2007; 98:1206-1214.
60. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000; 103:843-852.
61. Wu ZZ, Chow KP, Kuo TC, Chang YS, Chao CC. Latent membrane protein 1 of Epstein-Barr virus sensitizes cancer cells to cisplatin by enhancing NF-kappaB p50 homodimer formation and downregulating NAPA expression. Biochemical pharmacology. 2011; 82:1860-1872.
62. Hallikas O, Palin K, Sinjushina N, Rautiainen R, Partanen J, Ukkonen E, Taipale J. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell. 2006; 124:47-59.
63. Bottomly D, Kyler SL, McWeeney SK, Yochum GS. Identification of [beta]-catenin binding regions in colon cancer cells using ChIP-Seq. Nucleic acids research. 2010; 38:5735-5745.